MyFinsight
Home
Blog
About
Contact
Download
Download image
BRUKINSA
$3,928,489K
(48.57%↑ Y/Y)
Tislelizumab
$737,304K
(18.76%↑ Y/Y)
XGEVA
$305,979K
(36.35%↑ Y/Y)
BLINCYTO
$104,224K
(40.22%↑ Y/Y)
Other
$83,691K
(39.39%↑ Y/Y)
KYPROLIS
$74,974K
(13.30%↑ Y/Y)
Pobevcy
$47,400K
(-11.42%↓ Y/Y)
Amgen Royalty Revenue
$40,733K
Novartis Broad Markets
Revenue
$17,598K
Collaboration Other
$2,641K
Product
$5,282,061K
(1369.25%↑ Y/Y)
Collaboration
$60,972K
(1854.86%↑ Y/Y)
Total revenues
$5,343,033K
(41.37%↑ Y/Y)
Gross profit
$4,674,493K
(45.34%↑ Y/Y)
Cost of sales -
product-Product
$668,540K
Income (loss) from
operations
$447,136K
(178.69%↑ Y/Y)
Interest income
$70,505K
Total operating
expenses
$4,227,357K
(11.71%↑ Y/Y)
Income (loss) before
income taxes
$416,854K
(178.21%↑ Y/Y)
Interest expense
$58,234K
Other (expense)
income, net
-$42,553K
(-236.71%↓ Y/Y)
Research and development
$2,145,868K
(9.86%↑ Y/Y)
Selling, general and
administrative
$2,081,489K
(13.68%↑ Y/Y)
Net income (loss)
$286,933K
(144.50%↑ Y/Y)
Income tax expense
$129,921K
(16.22%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)